inability to induce immune responses. Cell surfaceexpressed trophoblast HLA-G can suppress immune responses by binding to inhibitory receptors. The HLA-G receptors reported to date are the leukocyte Ig-like receptors (LILR) B1 and B2, killer cell Ig-like receptor (KIR) 2DL4, CD160 and CD8 [2] [3] [4] (Fig. 1) . Previous reports clearly demonstrate that LILRB1 and LILRB2 preferentially bind to HLA-G compared with other classical MHCI [5] . Intriguingly, HLA-G is expressed in several unusual forms in addition to the conventional heterotrimer, associated with b2m and peptide, made by all classical MHCI. These include: (i) a disulfide-linked b2m-associated dimer; (ii) a b2m-free heavy chain, (iii) its disulfide-linked dimer, and (iv) domain-deleted and soluble splice variants [6] . Previous in vitro studies using either recombinant proteins, transfectants or cell lines demonstrated that HLA-G can exist as a disulfide-linked dimer of the conventional b2m-associated form (and in some cases, trimeric and oligomeric forms) [7, 8] . In this issue, Apps et al. [9] demonstrate that significant amounts of the b2m-associated HLA-G dimer are expressed at the cell surface of normal first trimester trophoblast cells. Furthermore, they also found that LILRB1 is the principal ligand for the HLA-G dimer. These results are consistent with previous studies showing that the HLA-G dimers bind with greater avidity to LILRB1/2 and signal more strongly through LILR than monomeric HLA-G and other classical MHCI [10, 11] (Fig. 1) . Therefore, the HLA-G dimer presumably has a significantly pivotal in vivo role in maternal-fetal interface, in comparison with the monomeric form. In addition to the crystal structure of the HLA-G monomer [12] , the recent structural study [10] showed that the disulfide-linked dimer exhibits an oblique configuration exposing two upward facing LILR/CD8 binding sites, readily accessible to receptors, explaining the increased avidity. On the other hand, the peptide-binding grooves are very close, possibly preventing T cell receptor binding ( Fig. 1 ).
There are some reports demonstrating the existence of a b2m-free heavy chain form of HLA-G. Gonen-Gross et al. [11] demonstrated placental expression of the b2m-free form of HLA-G by in situ immunostaining. Furthermore, Morales et al. [13] recently showed that villous cytotrophoblast cells (vCTB) express the dimeric form of b2m-free HLA-G. Based on these results, Hunt et al. [14] summarized the expression pattern of HLA-G variants in placenta. These results are different from those of Apps et al. [9] with regards to the b2m association of HLA-G dimer in placenta, and might be a consequence of the different cell populations used in each study. Recent reports [11, 15] have shown that LILRB2 can recognize the b2m-free MHCI, but LILRB1 cannot (Fig. 1) . Therefore, b2m-free HLA-G confers an inhibitory effect selectively on LILRB2-expressing cells, such as antigen-presenting cells (APC). Furthermore, Kollnberger et al. [16] showed that b2m-free HLA-B27 dimer binds to KIR3DL2 and KIR3DL1 as well as LILRB2. Thus, it will be of great interest to see whether b2m-free HLA-G dimer binds to LILRB and KIR with greater avidity than monomer.
Emerging studies have revealed the potential roles of various forms of MHCI, including b2m-free MHCI (and its homodimer) and associated forms with other unrelated molecules [17] . As described above, HLA-G can exist in similar forms, but possesses unique cysteine residues distinct from other MHCI, including Cys42, which is involved in disulfide-linked dimer formation without any conformational changes. Therefore, both b2m-associated and -free forms of the HLA-G dimer could have distinct roles in immune suppression from those of normal MHCI.
The soluble form of HLA-G (sHLA-G) is secreted and/ or shed from the cell surface toward the decidua area. sHLA-G can inhibit immune responses of LILRB1/2-expressing cells in the decidua and can also interact with Figure 1 . Receptor recognition of the different forms of HLA-G at the maternal-fetal interface. HLA-G can be expressed in various forms in placenta. The structures of b2m-associated HLA-G monomer and dimer are shown. LILRB1 (light blue), which is expressed on decidual antigen-presenting cells (APC) and subsets of NK and T cells, binds to only b2m-associated forms of HLA-G monomer and dimer. LILRB2 (dark blue), whose expression is restricted to decidual APC, binds to both b2m-associated and -free forms of HLA-G monomer and dimer. LILRB1 and LILRB2 presumably bind to HLA-G dimer more strongly than its monomer. The thickness of the arrows corresponds to the signal strength. Both membrane-bound and soluble forms likely inhibit the immune responses of LILRBexpressing cells. On the other hand, the HLA-G recognition of CD160 and KIR2DL4 still remains unclear.
CD160 expressed on the surface of endothelial cells [18] , possibly resulting in the anti-angiogenic effects on uterine vascular remodeling in pregnancy. By contrast, sHLA-G binds to KIR2DL4 at the cell surface and is internalized into endosomes, whereas the membranebound form of HLA-G cannot, thus stimulating proinflammatory and pro-angiogenic cytokines production, which would be helpful in increasing blood supply to the placenta [19] . Using a killing assay, Yan et al. [20] revealed that the KIR2DL4 binding site is located in the C-terminal peptide-binding site of the HLA-G a1 helix. This suggests that the HLA-G dimer may not be able to bind to KIR2DL4 because of the close proximity of the peptide-binding grooves. However, without further biochemical evidence it is not possible to draw any definitive conclusions. Further in-depth investigations, especially comprehensive binding studies with recombinant proteins, will clarify the precise role of HLA-G monomer and dimer interactions with KIR2DL4 and CD160 in immune regulation.
Taken together, the current evidence and the results from Apps et al. [9] strongly suggest that LILR recognition of HLA-G dimers has a pivotal role to play in immune suppression at the maternal-fetal interface, possibly contributing to the prevention of pregnancy complications such as pre-eclampsia and recurrent abortion. Further detailed analysis of the interaction of HLA-G with LILR and KIR families, CD160 and maybe as yet-unidentified receptors will provide a clear molecular basis of how these interactions may be involved in immune suppression and the control of angiogenesis in vivo. These studies may also provide future avenues of research with potential clinical applications.
